Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
AI · cancer
Намерени 1,748 изпитвания за "cancer" Стр. 75 от 88
Active (not recruiting) Phase 3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Urothelial Cancer

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

Начало: 23.03.2018 Край: 31.12.2026 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +22 Janssen Research & Development, LLC NCT03390504
Active (not recruiting)
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
Oropharyngeal Cancer

The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial

Начало: 26.01.2018 Край: 15.08.2028 Възраст: от 18 г. Treatment
Australia, Canada London Health Sciences Centre Research Institute OR Law NCT03210103
Active (not recruiting) Phase 1/2
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Breast Cancer

This study is being done to assess the feasibility of pembrolizumab (study drug) combined with standard radiation to the tumor (tumor boost) before patients undergo standard treatment that can consist of one or more of the following: breast-conserving surgery, radiation to the entire breast/chest wall after surgery, and chemotherapy. Study participants will receive two doses of the study drug intravenously (through the vein) before their planned breast surgery or chemotherapy. The study drug will be administered three weeks apart. At the time of the second dose, radiation to the tumor in the affected breast will be given. This type of radiation treatment is called a "tumor boost", which is a standard part of radiation therapy for breast cancer that may occur either before or after planned breast-conserving surgery. Patients will receive breast surgery or begin chemotherapy approximately six weeks after your first dose of the study drug.

Начало: 22.12.2017 Край: 07.12.2030 Възраст: от 18 г.
United States Stephen Shiao NCT03366844
Active (not recruiting) Phase 1
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Breast Cancer

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormone-releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.

Начало: 24.11.2017 Край: 31.07.2026 Възраст: от 18 г. Treatment
Australia, South Korea, Spain +2 Genentech, Inc. NCT03332797
Active (not recruiting)
Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer
Gynecologic Cancer

The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.

Начало: 13.11.2017 Край: 15.09.2027 Възраст: от 18 г.
United States Brigham and Women's Hospital NCT03277469
Active (not recruiting)
PRecISion Medicine for Children With Cancer
Childhood Cancer Childhood Solid Tumor Childhood Brain Tumor Childhood Leukemia +2

This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.

Начало: 05.09.2017 Край: 01.12.2032 Възраст: до 21 г.
Australia Sydney Children's Hospitals Network NCT03336931
Active (not recruiting)
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
Early Stage Breast Carcinoma

This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

Начало: 21.08.2017 Край: 01.04.2028 Възраст: от 50 г. Treatment
Argentina, Australia, Chile +6 Breast Cancer Trials, Australia and New Zealand NCT02889874
Active (not recruiting) Phase 3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Breast Cancer

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Начало: 12.07.2017 Край: 01.05.2029 Възраст: от 18 г. Treatment
Argentina, Australia, Austria +35 Eli Lilly and Company NCT03155997
Active (not recruiting) Phase 3
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
HER-2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

Начало: 21.06.2017 Край: 31.07.2026 Възраст: от 18 г. Treatment
Australia, France, Germany +5 Alliance Foundation Trials, LLC. NCT02947685
Active (not recruiting) Phase 1/2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Non-Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Any Solid Tumor

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Начало: 02.05.2017 Край: 01.02.2027 Възраст: от 12 г. Treatment
Australia, Canada, Denmark +12 Eli Lilly and Company NCT03157128
Active (not recruiting) Phase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma Thymic Carcinoma

Background: Thymoma and thymic carcinoma are cancers originating in the thymus gland. Platinum-based chemotherapy is standard treatment for them. But not uncommonly, the disease returns and people need more treatment to keep the cancer from growing. The drug Avelumab could help the immune system fight cancer. Objective: To test if avelumab is safe and well-tolerated, and is effective in treating relapsed or refractory thymoma and thymic carcinoma. Eligibility: People ages 18 and older with thymoma or thymic carcinoma that has returned or progressed after platinum-containing chemotherapy Design: Participants will be screened with: * Blood, urine, and heart tests * Scan: They lie in a machine that takes pictures of the body. * Physical exam * Medical history * Biopsy: a needle removes a piece of tumor. Samples can be from a previous procedure, although it is desirable to undergo a new biopsy. Participants will have treatment in 2-week cycles. They will continue until the side effects are not tolerable or their disease gets worse. Visits at the following time points are required per protocol. Patients who respond to treatment or have durable stability after at least 12 months of therapy may undergo a dose de-escalation regimen to continue on therapy. * Every 2 weeks: Participants will get avelumab by infusion in a vein (IV). They will get diphenhydramine (benadryl) and acetaminophen (tylenol) by mouth or IV before receiving avelumab to decrease the chances of developing a reaction to avelumab. They will have blood, urine, and heart tests periodically. * Cycles 4 and 7, then every 6 weeks: Scans will be performed to look for shrinkage or growth of tumor. * Cycle 4: Participants will be offered a chance to undergo a biopsy. * 2-4 weeks after stopping treatment: Blood, urine, and heart tests will be performed. Participants might undergo a scan. * 10 weeks after stopping treatment: Blood, urine, and heart tests. * About 6 months after stopping treatment, then every 3 months: Participants will have scans andcan allow genetic testing on their blood and tissue samples.

Начало: 19.04.2017 Край: 30.06.2027 Възраст: от 18 г.
United States National Cancer Institute (NCI) NCT03076554
Active (not recruiting) Phase 2
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
Chronic Atrophic Gastritis Gastric Carcinoma

This randomized phase IIb trial studies how well curcumin works in preventing gastric cancer in patients with chronic atrophic gastritis and/or gastric intestinal metaplasia. Curcumin is an antioxidant compound found in plants that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Начало: 04.04.2017 Край: 01.04.2027 Възраст: от 21 г.
Honduras, Puerto Rico National Cancer Institute (NCI) NCT02782949
Active (not recruiting) Phase 3
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Small Cell Lung Carcinoma Extensive Disease

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Начало: 27.03.2017 Край: 31.12.2026 Възраст: 18–130 г.
Argentina, Austria, Brazil +20 AstraZeneca NCT03043872
Active (not recruiting) Phase 3
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Urothelial Cancer

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.

Начало: 24.03.2017 Край: 15.05.2026 Възраст: от 18 г. Treatment
Argentina, Australia, Brazil +25 Bristol-Myers Squibb NCT03036098
Active (not recruiting) Early Phase 1
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Triple-Negative Breast Carcinoma

This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.

Начало: 07.11.2016 Край: 30.04.2028 Възраст: от 18 г.
United States M.D. Anderson Cancer Center NCT02744053
Active (not recruiting) Phase 2
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
Malignant Digestive System Neoplasm Metastatic Head and Neck Carcinoma Metastatic Kidney Carcinoma Metastatic Malignant Neoplasm in the Spine +9

This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal cord. Thermal ablation uses a laser to heat tumor tissue and helps to shrink the tumor by destroying tumor cells. Stereotactic radiosurgery delivers a large dose of radiation in a short time precisely to the tumor, sparing healthy surrounding tissue. Combining thermal ablation with stereotactic radiosurgery may be a better way to control cancer that has spread to the spine and is at risk for compressing the spinal cord.

Начало: 29.08.2016 Край: 28.10.2027 Възраст: от 18 г.
United States M.D. Anderson Cancer Center NCT02713269
Active (not recruiting) Phase 3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Non-small Cell Lung Cancer

The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.

Начало: 01.06.2016 Край: 31.12.2025 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +17 Xcovery Holdings, Inc. NCT02767804
Active (not recruiting) Phase 1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer

The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

Начало: 24.05.2016 Край: 31.12.2026 Възраст: от 18 г. Treatment
Australia, Canada, China +7 Janssen Research & Development, LLC NCT02609776
Active (not recruiting) Phase 2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Biliary Tract Cancer Metastatic Cancer Advanced Cancer

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Начало: 19.05.2016 Край: 01.12.2026 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +13 Eli Lilly and Company NCT02711553
Active (not recruiting) Phase 1/2
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Triple Negative Breast Cancer

The goal of this study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.

Начало: 23.02.2016 Край: 01.12.2026 Възраст: от 18 г.
United States Providence Health & Services NCT02734290
1 … 73 74 75 76 77 … 88